GSK (GSK) discloses 4.08B total voting rights after treasury shares

Rhea-AI Filing Summary

GSK plc reported its share capital and voting rights position as of 31 December 2025. The company’s issued share capital consisted of 4,315,445,026 ordinary shares of 31 ¼ pence each, with 240,019,489 of these shares held in treasury and therefore not carrying voting rights. As a result, the total number of voting rights in GSK is 4,075,425,537. Shareholders can use this figure to determine whether they need to notify GSK and the UK Financial Conduct Authority of any interests or changes in their shareholdings under the Disclosure Guidance and Transparency Rules.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 5 January 2026, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 31 December 2025 consisted of 4,315,445,026 shares of 31 ¼ pence each ('Ordinary Shares'), of which 240,019,489 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,075,425,537. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

5 January 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: January 05, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What total voting rights did GSK (GSK) report as of 31 December 2025?

As of 31 December 2025, GSK reported a total of 4,075,425,537 voting rights in the company. This is the figure shareholders should use when assessing notification thresholds under the UK Disclosure Guidance and Transparency Rules.

How many GSK (GSK) ordinary shares were in issue and how many were held in treasury?

GSK’s issued share capital consisted of 4,315,445,026 ordinary shares of 31 ¼ pence each, of which 240,019,489 ordinary shares were held in treasury as of 31 December 2025.

Why does GSK’s reported total voting rights number matter to shareholders?

The total of 4,075,425,537 voting rights is used by shareholders as the denominator to calculate whether their holdings reach thresholds that require them to notify their interest or changes in interest under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

What is the nominal value of GSK (GSK) ordinary shares mentioned in this report?

Each GSK ordinary share referenced in the report has a nominal value of 31 ¼ pence.

Who signed this GSK (GSK) report on behalf of the company?

The report was signed by Victoria Whyte, acting as an authorised signatory for and on behalf of GSK plc, in her role as Company Secretary.

What is GSK’s business focus as described in this report?

GSK describes itself as a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.